A systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer (Q37966610)

26 August 2017

title

A systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer (English)

1 reference

26 August 2017

1 reference

1 reference

Sudha Sundar

1

1 reference

26 August 2017

Jianhua Wu

2

1 reference

26 August 2017

Kathryn Hillaby

3

1 reference

26 August 2017

Jason Yap

4

1 reference

26 August 2017

Richard Lilford

5

1 reference

26 August 2017

language of work or name

English

0 references

publication date

8 December 2011

1 reference

26 August 2017

1 reference

26 August 2017

volume

125

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

493-499

1 reference

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2011.12.420

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2011.12.420

Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2011.12.420

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2011.12.420

Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2011.12.420

The relationship between progression-free and post-progression survival in treating four types of metastatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2011.12.420

Estimating changes in overall survival using progression-free survival in metastatic breast and colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2011.12.420

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2011.12.420

Exploring and validating surrogate endpoints in colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2011.12.420

Progression-free survival is a surrogate for survival in advanced colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2011.12.420

Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2011.12.420

Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2011.12.420

Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2011.12.420

10.1016/J.YGYNO.2011.12.420

7 January 2021

Identifiers

DOI

1 reference

26 August 2017

1 reference